MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Heron Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

1.49

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.45

Max

1.51

Galvenie mērījumi

By Trading Economics

Ienākumi

-15M

-17M

Pārdošana

1M

38M

Peļņas marža

-45.783

Darbinieki

122

EBITDA

-12M

-14M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+202.01% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 26. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

57M

273M

Iepriekšējā atvēršanas cena

1.49

Iepriekšējā slēgšanas cena

1.49

Ziņu noskaņojums

By Acuity

37%

63%

118 / 361 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Heron Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. janv. 23:29 UTC

Karstas akcijas

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026. g. 16. janv. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026. g. 16. janv. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026. g. 16. janv. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026. g. 16. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. janv. 21:48 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026. g. 16. janv. 21:41 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026. g. 16. janv. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026. g. 16. janv. 20:44 UTC

Peļņas

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026. g. 16. janv. 20:42 UTC

Tirgus saruna

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026. g. 16. janv. 20:28 UTC

Tirgus saruna

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026. g. 16. janv. 19:12 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

2026. g. 16. janv. 18:53 UTC

Tirgus saruna

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

2026. g. 16. janv. 18:41 UTC

Tirgus saruna

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

2026. g. 16. janv. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026. g. 16. janv. 16:32 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

2026. g. 16. janv. 16:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Heron Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

202.01% augšup

Prognoze 12 mēnešiem

Vidējais 4.5 USD  202.01%

Augstākais 6 USD

Zemākais 3 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Heron Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

4

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.0001 / 2.42Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

118 / 361 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat